The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued. #melsm onclive.com/view/merck-dis…

The FDA has granted breakthrough therapy designation to petosemtamab in recurrent or metastatic head and neck squamous cell carcinoma. U.S. FDA #oncology onclive.com/view/petosemta…

In this episode of #OncLiveOnAir , Jubilee Brown, of Atrium Health, discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer. #ovca #Oncology

Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care. Samilia Obeng-Gyasi, MD, MPH The James #bcsm #oncology onclive.com/view/identifyi…

We've rounded up the important regulatory approvals made by the FDA in April 2024, including the data that supported the decisions and expert insights on the clinical implications of these pipeline updates. U.S. FDA #oncology onclive.com/view/onclive-s…

Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients. Jean Koff, MD Winship Cancer Institute of Emory University #leusm #MedTwitter onclive.com/view/pirtobrut…

Treatment with relatlimab and nivolumab plus chemotherapy did not meet the primary end point of improved ORR vs nivolumab plus chemotherapy in the phase 2 RELATIVITY-060 trial in untreated gastric/GEJ cancer. Journal of Clinical Oncology #gastriccancer #oncology #MedTwitter onclive.com/view/relatlima…

Repotrectinib has been approved by China’s National Medical Products Administration for the treatment of patients with ROS1-positive NSCLC. #lcsm #oncology onclive.com/view/repotrect…

Compounding RAF/MEK inhibition and FAK inhibition through the combination of avutometinib and defactinib is opening novel areas of exploration in the treatment of patients with low-grade serous ovarian cancer. Jubilee Brown #ovca #oncology onclive.com/view/avutometi…

The BCMA-targeted CAR T-cell therapies cilta-cel and ide-cel received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma. Dana-Farber The Tisch Cancer Institute #mmsm #oncology onclive.com/view/the-benef…

.Somedeb Ball, of Vanderbilt-Ingram Cancer Center, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes. #oncology #hematology onclive.com/view/dr-ball-o…

Innovative clinical trials exploring pharmacokinetics and low-dose therapy with agents are at the forefront of investigations in AML, ALL, and glioblastoma multiforme. University Hospitals #mmsm #lymsm #oncology #btsm onclive.com/view/aml-all-a…

The coprimary end point of the KEYNOTE-B21 trial, OS, was not formally evaluated, as superiority was not achieved for DFS with adjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy in high-risk endometrial cancer. #gynsm #oncology onclive.com/view/adjuvant-…

The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors. #oncology #medtwitter onclive.com/view/cx-904-ge…

The FDA has granted a breakthrough device designation to Teal Wand, which allows for at-home collection of a vaginal sample, which users then mail to a laboratory. #gynsm #oncology onclive.com/view/fda-grant…

Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial. Dr. Maurie Markman City of Hope #oncology onclive.com/view/improved-…

Novel targetable pathways are emerging in the AML research field on the heels of success with standard FLT3 and IHD1/2 inhibitors, signaling a new era of prolonged responses and improved quality of life. Naval Daver, M.D. MD Anderson Cancer Center #leusm #oncology onclive.com/view/commitmen…

China's NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma. #oncology #medtwitter onclive.com/view/ibi343-re…

Across the 14 studies included in this analysis, rIFNα discontinuation rates ranged from 4.6% to 37% over median durations of 0.4 to 6.3 years. Ghaith Abu-Zeinah, MD Weill Cornell Medicine Blood Advances #mpnsm #oncology onclive.com/view/pooled-an…

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC. #lcsm #oncology onclive.com/view/nivolumab…